The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers. The Phase I study is a dose-escalation trial in which cohorts of healthy volunteers will receive single doses of SGN-70.
The clinical trial will be conducted in Switzerland and is expected to accrue approximately 60 volunteers.
According to the company, the CD70 antigen is highly expressed on activated T- and B-cells but not resting lymphocytes, and has been associated with a variety of autoimmune and inflammatory disorders.